The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...